none

PAIN MEDS BEFORE THE ACCC AGAIN

07-12-2017
by 
in 

Just one year ago pain med brand Nurofen was slugged with a $6 million dollar fine for making false claims about pain relief; now Voltaren is under fire for the exact same issue.

The ACCC has filed formal proceedings in the Federal Court against GlaxoSmithKline and Novartis, alleging the drugmakers misled consumers in the marketing of Voltaren Emulgel and Osteo Gel pain relief products.

Osteo Gel is marketed as being formulated for treating osteoarthritis conditions, but both Voltaren and Osteo Gel contain the same active ingredient: diclofenac diethylammonium gel 11.6mg/g.

While the recommended retail price of Osteo Gel 150 is $3 more expensive than Emulgel 150g at $28.99 compared with $25.99, the ACCC said the former was found in-store at a mark-up of up to $7.50, or 33 per cent.

“We’re so disappointed that having taken the Nurofen case, with all of the publicity around it, that we find this sort of behaviour still continuing,” Mr Sims said. 

Mr Sims said if the ACCC won the case, the watchdog would be seeking an even higher penalty than against Nurofen. “If we’re successful, we’d be looking at trying to get an even stronger deterrence message out there” he said.

Mr Sims said the ACCC was also concerned that the products were targeted at older consumers. “We’re always concerned with conduct that affects consumers who could be seen as slightly more vulnerable,” he said.

“What was happening here is that they were saying you’ve got a product that is specifically formulated for treating osteoarthritis, particularly in the knees and fingers, and indeed saying that also it’s more effective than Emulgel.

“Our concerns were not only that consumers were paying more for Osteo Gel, but they could actually buy both products and have them in their medical cabinet, thinking they treat different things.”

GSK acquired the Voltaren brand from Novartis in 2016 but the products have been sold since 2010. In March this year, GSK amended the Osteo Gel packaging to include the statement, “Same effective formula as Voltaren Emulgel”, but the ACCC alleges the amended packaging is also likely to be misleading.

Related news & editorials

  1. 13.12.2018
    13.12.2018
    by      In
    After a long stint as the Asia-Pacific Managing Director of 600 Machine Tools, Cliff Purser is retiring from his post in Sydney, and returning to live in New Zealand.
    The genial Englishman has led the 600 team in Australia since transferring in November 2004 from the position of New Zealand... Read More
  2. 13.12.2018
    13.12.2018
    by      In
    Adelaide has been chosen as the headquarters of the newly established Australian Space Agency.
    The Australian Space Agency was officially launched on 1st July and received $41 million over four years from 2018-19 in the federal budget to “grow the Australian space industry,” including $26 million... Read More
  3. 12.12.2018
    12.12.2018
    by      In
    There are very few companies in Australia that can point to half a century of experience in electronic control systems, but Plant Control & Automation is one that certainly can.
    The company was founded in Sydney in 1968 by Adrian Smith, a young engineer who immediately set about designing and... Read More
  4. 11.12.2018
    11.12.2018
    by      In
    A-Safe Australasia has capped off a record year with a move to new premises. And while the company’s new base at 177-179 Power Street, Glendenning in Sydney’s west is just a few hundred metres from its old home at 197 Power Street, it provides the company with more than double the office and... Read More